PDE5 inhibition with sulindac sulfide (SS) was shown to promote cGMP accumulation, activation of PKG which, in turn, caused inhibition of cell growth and apoptosis in breast cancer cell lines (124), representing a viable strategy for breast cancer treatment. This evidence concerns the gene PDE5A and breast cancer.